Clinical Trials Directory

Trials / Conditions / ASCVD

ASCVD

30 registered clinical trials studyying ASCVD13 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingDuke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Fa
NCT07117695
Duke UniversityN/A
Not Yet RecruitingDevelopment and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multi
NCT07491978
Tarumanagara University
Not Yet RecruitingAdherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVa
NCT07522645
Kaiser PermanenteN/A
RecruitingEffects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
NCT06691217
Massachusetts General HospitalPhase 2
Not Yet RecruitingEfficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
NCT07303777
Atom Therapeutics Co., LtdPhase 2
Active Not RecruitingINcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASC
NCT07417618
Brigham and Women's Hospital
RecruitingThe Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks
NCT07270887
General Hospital of Shenyang Military Region
Enrolling By InvitationImproving Lipid Optimization Quality and Treatment Options in ASCVD
NCT06960655
Brigham and Women's HospitalN/A
Active Not RecruitingACHIEVE Pilot Statins for Vascular Protection
NCT06551701
Duke University
RecruitingComparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes M
NCT06767774
Korea University Anam HospitalPhase 4
RecruitingA Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471
Hasten Biopharmaceutical Co., Ltd.Phase 3
Not Yet RecruitingNPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe
NCT06641661
Qianfoshan Hospital
Active Not RecruitingNotification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NO
NCT05858879
Stanford UniversityN/A
RecruitingTest 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitali
NCT06471036
Duke UniversityN/A
CompletedTelehealth Group Counseling and Preventive Care for Women
NCT06404515
Weill Medical College of Cornell UniversityN/A
CompletedStudy of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597
NewAmsterdam PharmaPhase 3
Active Not RecruitingProspective Cohort Study of Panvascular Disease
NCT06295861
Second Affiliated Hospital, School of Medicine, Zhejiang University
UnknownStudy on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
NCT05976893
Xiang XiePhase 4
Enrolling By InvitationComparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Di
NCT05579626
Seung-Whan Lee, M.D., Ph.D.Phase 4
TerminatedLate Subclinical Cardiovascular Disease in Testicular Cancer Survivors
NCT05611307
Indiana University
RecruitingPREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Brigham and Women's HospitalPhase 4
Active Not RecruitingRandomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotei
NCT05088759
Brigham and Women's HospitalN/A
TerminatedThe Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
NCT04197453
Amgen
UnknownCardiometabolic Syndrome Response to Therapeutic Lifestyle Changes
NCT04093440
Holy Cross Hospital, FloridaN/A
CompletedTrial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
NCT03814187
Novartis PharmaceuticalsPhase 3
UnknownThyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)
NCT03606824
Shaochun.LiN/A
CompletedHigh-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and
NCT03474562
Yuhan CorporationPhase 4
CompletedHigh-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
NCT03494270
Yuhan CorporationPhase 4
CompletedInclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein C
NCT03399370
The Medicines CompanyPhase 3
CompletedInclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
NCT03400800
The Medicines CompanyPhase 3